Azora Therapeutics, Inc. (AZR) Revenue, Earnings & Financial Statements
$3.81NASDAQ: AZRMarket Cap $10.00M
Data as of Nov 16, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Azora Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $8.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Income Statement — 1 Years (USD millions)
Metric
2025
Revenue
$0
Operating Expenses
$8.0M
Operating Profit
−$8.0M
Other Income
$0
Interest
$0
Depreciation
$0
Profit Before Tax
−$8.0M
Tax rate (%)
0.0%
Net Profit
−$8.0M
EPS
−$11.93
Quarterly Results — Last 4 Quarters (USD millions)
Metric
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
Operating Expenses
$2.0M
$2.0M
$52.0M
$8.0M
Operating Profit
−$2.0M
−$2.0M
−$52.0M
−$8.0M
Interest
$0
$0
$0
$0
Profit Before Tax
−$2.0M
−$2.0M
−$52.0M
−$65.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
Net Profit
−$2.0M
−$2.0M
−$52.0M
−$65.0M
EPS
−$1.80
−$1.48
−$11.25
−$4.52
Balance Sheet — 1 Years (USD millions)
Metric
2025
Total Assets
$7.0M
Current Assets
$6.0M
Cash
$6.0M
Inventory
$0
Receivables
$0
Fixed Assets
$0
Capital Work in Progress
$0
Investments
$0
Other Assets
$0
Total Liabilities
$2.0M
Current Liabilities
$1.0M
Borrowings
$0
Other Liabilities
$2.0M
Equity
$0
Reserves
$5.0M
For Azora Therapeutics, Inc., operating cash flow was positive in 0 of 9 reported years; free cash flow in the latest year was negative at $6.0M; free cash flow was positive in 0 of 9 years.
Cash Flow Statement — 9 Years (USD millions)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
$0
−$2.0M
−$6.0M
−$8.0M
−$12.0M
−$11.0M
−$7.0M
−$7.0M
−$6.0M
Investing Cash Flow
$0
—
—
$0
$0
—
$2.0M
—
$0
Financing Cash Flow
$0
$6.0M
$9.0M
$6.0M
$14.0M
$9.0M
$4.0M
$8.0M
$8.0M
Net Cash Flow
$0
$4.0M
$3.0M
−$2.0M
$2.0M
−$2.0M
−$1.0M
$1.0M
$2.0M
Free Cash Flow
$0
−$2.0M
−$6.0M
−$8.0M
−$12.0M
−$11.0M
−$7.0M
−$7.0M
−$6.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.00
EV / EBITDA
-0.16
FCF Yield
-92.95%
Quick Ratio
4.43
Interest Coverage
—
Return 1Y
-53.82%
Return 3Y
-92.74%
Return 5Y
-99.82%
Azora Therapeutics, Inc. (AZR) financials — frequently asked questions
What is Azora Therapeutics, Inc.'s annual revenue?
Azora Therapeutics, Inc. (AZR) reported annual revenue of $0 in its most recent fiscal year.
What is Azora Therapeutics, Inc.'s net profit?
Azora Therapeutics, Inc. (AZR) reported a net loss of $8.0M in its most recent fiscal year.
What is AZR EV/EBITDA?
Azora Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.16. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Medical - Pharmaceuticals stocks